Long non-coding RNAs: A view to kill ovarian cancer

Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188584. doi: 10.1016/j.bbcan.2021.188584. Epub 2021 Jun 19.

Abstract

An emerging role of long non-coding RNAs (lncRNAs) in tumor progression has been revealed in the last decade. Through interactions with nucleic acids and proteins, lncRNAs could act as enhancers, scaffolds or decoys for a number of oncoproteins and tumor suppressors. The aberrant lncRNA expression or mutations are often associated with changes in a variety of cellular processes, including proliferation, stress response and cell death. Here, we will focus on the tumor-associated lncRNAs in ovarian cancer according to their contribution to cancer hallmarks, such as intense proliferation, cell death resistance, altered energy metabolism, invasion and metastasis, and immune evasion. Moreover, the potential clinical implications of lncRNAs and their significance for the diagnosis, prognosis and therapy of ovarian cancer will be discussed.

Keywords: Cancer hallmarks; LncRNAs; Ovarian cancer; Prognosis, targeted therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • CRISPR-Cas Systems
  • Drug Resistance, Neoplasm
  • Female
  • Gene Editing
  • Gene Expression Regulation, Neoplastic
  • Genetic Therapy
  • Humans
  • Oligonucleotides, Antisense / therapeutic use
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / metabolism*
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Oligonucleotides, Antisense
  • RNA, Long Noncoding